A comparison of dosimetric parameters between tomotherapy and three-dimensional conformal radiotherapy in rectal cancer

Radiation Oncology

Jong Hoon Lee¹  Hyo Chun Lee¹  Jae Suk Cheon²  Dong Min Jeon²  Hong Seok Jang²  Joo Hwan Lee¹  Mina Yu¹ 

[1] Department of Radiation Oncology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93-6 Ji-dong Paldal-gu, Suwon, Kyeonggi-do, Republic of Korea;Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

关键词: Tomotherapy;    Rectal cancer;    Preoperative radiotherapy;    Dosimetry;    Conformal;   

Others  :  1153414
DOI  :  10.1186/1748-717X-8-181

 received in 2013-02-27, accepted in 2013-07-08,  发布年份 2013

【 摘 要 】

Purpose

Tomotherapy for intensity-modulated radiation has been demonstrated to reduce unnecessary irradiations to adjacent organs at risk (OARs). The purpose of this study was to compare the dosimetric parameters between Tomotherapy and three-dimensional conformal radiotherapy (3D-CRT) in rectal cancer patients.

Materials and methods

We redesigned three-dimensional conformal plans for 20 rectal cancer patients who had received short-course preoperative radiotherapy with Tomotherapy. The target coverage for 3D-CRT and Tomotherapy was evaluated with the following including the mean dose, V_nGy, D_min, D_max, radiation conformality index (RCI), and radical dose homogeneity index (rDHI).

Results

The mean PTV dose for Tomotherapy is significantly higher than that observed for the 3D-CRT (p = 0.043). However, there is no significant difference in the V_23.25Gy, V_26.25Gy, V_27.5Gy, and RCI values between Tomotherapy and 3D-CRT. However, the average rDHI (p < 0.001) value for Tomotherapy was significantly lower than that reported for the 3D-CRT. Tomotherapy significantly lowered the mean level of irradiation doses to the bladder, small bowel, and femur heads as compared to 3D-CRT.

Conclusions

Tomotherapy could produce a favorable target coverage and significant dose reduction for the OARs at the expense of acceptable dose inhomogeneity of the PTV compared with 3D-CRT in rectal cancer patients.

【 授权许可】

   
2013 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lee EH, Lee HY, Choi KS, Jun JK, Park EC, Lee JS: Trends in cancer screening rates among Korean men and women: results from the Korean National Cancer Screening Survey (KNCSS), 2004–2010. Cancer Res Treat 2011, 43(3):141-7.
• [2]Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740.
• [3]Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al.: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355(11):1114-23.
• [4]Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial N Engl J Med 1997, 336(14):980-987.
• [5]Kapiteijn E, Marijnen CAM, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl JMed 2001, 345(9):638-646.
• [6]Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93(10):1215-23.
• [7]Birgisson H, Pahlman L, Gunnarsson U, Glimelius B: Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg 2008, 95(2):206-13.
• [8]Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al.: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005, 23(9):1847-58.
• [9]Heron DE, Gerszten K, Selvaraj RN, King GC, Sonnik D, Gallion H, et al.: Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled. Gynecol Oncol 2003, 91(1):39-45.
• [10]Arbea L, Ramos LI, Martínez-Monge R, Moreno M, Aristu J: Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010, 5:17. BioMed Central Full Text
• [11]International Commission on Radiation Units and Measurements: Prescribing, recording and reporting photon beam therapy ICRU report 62. Bethesda, MD: International Commission on Radiation Units and Measurements; 1999. 2010
• [12]Luxton G, Hancock SL, Boyer AL: Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004, 59(1):267-284.
• [13]Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, et al.: Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117(15):3342-51.
• [14]National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: anal cancer. NCCN ANAL-B 2011.
• [15]Bosset JF, Meneveau N, Pavy JJ: Late intestinal complications of adjuvant radiotherapy of rectal cancers. Cancer Radiother 1997, 1(16):770-4.
• [16]Lee JH, Lee JH, Jang HS, Lee HC, Lee JW, Kang DG, et al.: Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions. Clin Exp Metastasis 2013, 30(5):643-50.
• [17]Nuyttens JJ, Robertson JM, Yan D, Martinez A: The variability of the clinical target volume for rectal cancer due to internal organ motion during adjuvant treatment. Int J Radiat Oncol Biol Phys 2002, 53(2):497-503.
• [18]Niemierko A, Goitein M: Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor. Radiother Oncol 1993, 29(2):140-147.
• [19]Lee JH, Kim SH, Kim JG, Cho HM, Shim BY: Preoperative Chemoradiotherapy (CRT) followed by laparoscopic surgery for rectal cancer: predictors of the tumor response and the long-term oncologic outcomes. Int J Radiat Oncol Biol Phys 2011, 81(2):431-8.
• [20]Lee JH, Jang HS, Kim JG, Cho HM, Shim BY, Oh ST, et al.: Lymphovascular invasion is a significant prognosticator in rectal cancer patients Who receive preoperative chemoradiotherapy followed by total mesorectal excision. Ann Surg Oncol 2012, 19(4):1213-1221.
• [21]Lee JH, Kim DY, Nam TK, Yoon SC, Lee DS, Park JW, et al.: Long-term follow-up of preoperative pelvic radiotherapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04–01). Int J Radiat Oncol Biol Phys 2012, 84(4):955-61.
• [22]Lee JH, Jo IY, Lee JH, Yoon SC, Kim YS, Choi BO, et al.: The role of postoperative pelvic radiation in stage IV rectal cancer after resection of primary tumor. Radiat Oncol J 2012, 30(4):205-12.